INTRODUCTION
The development of next-generation sequencing platforms and the mapping of the human genome have transformed the field of pharmacogenetics into pharmacogenomics, thus expanding its scope from a candidate-driven approach to genome-wide studies of associations. The vast amount of genetic information opens new possibilities to describe and categorize the extent of genetic polymorphisms in the human genome at the population level.
Interindividual differences in drug pharmacokinetics (PK) and pharmacodynamics (PD) can cause the loss of treatment efficacy or give rise to adverse drug reactions (ADRs) with negative consequences for patients. In addition, ADRs can be as costly for society when they occur with the initial treatment for symptoms. 1 They are the prime cause of drug withdrawal from the market, resulting in significant costs for the pharmaceutical industry that have been calculated as approximately US$2.6 billion per new drug. 2 In recent decades, much research has aimed to identify the genetic basis for interindividual differences in drug response and toxicity; in particular, this work has resulted in a series of genomic drug labels by the Food and Drug Administration (FDA) 3 (http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm) and the European Medicines Agency 4 to optimize drug treatment. These studies also uncovered a vast repertoire of genetic variants with profound impact on drug metabolism, some of which have been successfully translated in clinical practice. 5 Much research has been focused on the cytochrome P450 (CYP) superfamily of genes because these are major contributors to drug metabolism, primarily in the liver. The impact of this variation on drug response and ADRs is extensive; recently, a comprehensive overview of the genetic variability within the CYP super gene family with important implications for personalized medicine was published. 6 Yet, a plethora of other genes such as other phase I enzymes, phase II conjugation enzymes, transporters, cytochrome reductases, and nuclear receptors, hereafter jointly termed "pharmacogenes, " also impact PK and PD directly or indirectly and can cause ADRs.
The SLC transporter family contains more than 300 genes with selectivity to structurally diverse compounds whose variants impact drug PK. One such example is given by genetic polymorphisms in SLCO1B1, a gene encoding the cellular transporter OATP1B1 that mediates influx of a wide variety of pharmaceutical substances like various statins, bosentan, and troglitazone. 10 The single-nucleotide variant (SNV) rs4149056 in SLCO1B1 (SLCO1B1*5) has been shown to profoundly influence statin uptake, resulting in lower inhibition of HMG-CoA and increased blood cholesterol levels. 11 Furthermore, the rs4363657 variant, which is in almost complete linkage disequilibrium with rs4149056, showed a strong association with statin-induced myopathy. 12 Inversely, treatment efficacy of the antidiabetes drug repaglinide is increased in variant carriers because hepatic uptake primes the compound for biotransformation into inactive metabolites. 13 In addition to transporters, phase II enzymes constitute an important class of pharmacogenes that are responsible for the detoxification and inactivation of drugs, mostly by transfer of chemical moieties that render the drug, toxin, or hormone more hydrophilic and facilitate excretion. Major phase II pathways include conjugation with glucuronides by UDPglucuronosyltransferases (UGTs), the addition of glutathione by glutathione-S-transferases (GSTs), and sulfonation catalyzed by sulfotransferases (SULTs). UGTs contribute to the biotransformation of drugs and other exogenous substances, such as tobacco smoke carcinogens as well as environmental and dietary pollutants.
14 Kinetics of these detoxification processes influence exposure to toxic or carcinogenic substances and thus can modify the susceptibility to exposure-induced diseases such as cancer.
14 Furthermore, genetic variants can influence the susceptibility to drug-induced toxicity, as exemplified by ADRs seen upon treatment with irinotecan. 15 GSTs catalyze the transfer of reduced glutathione to unipolar compounds such as halogenonitrobenzenes, quinones, and unsaturated carbonyls. 16 Genetic variants in GSTs affect the metabolism of busulfan and cyclophosphamide, two compounds with narrow therapeutic ranges used in conditioning prior to hematopoietic stem cell transplantations. 17 Sulfonation of drugs, environmental chemicals, and natural products via SULTs can result in detoxification or metabolic activation to mutagenic electrophiles. 18 In total, approximately 100 FDA-approved drugs are sulfated by SULTs, and variants have been shown to modulate drug sulfation. 19, 20 Nuclear receptors such as the aryl hydrocarbon receptor, constitutive androstane receptor, and pregnane X receptor can be important indirect determinants of PK and PD because they are key regulators mediating transcriptional responses to environmental stimuli and control expression of a variety of phase I and phase II enzymes and transporters. 21 Although approximately 35% of drugs with pharmacogenomic labels listed by the FDA are related to variants in the pharmacogenes analyzed in this article (http://www.fda.gov/ drugs/scienceresearch/researchareas/pharmacogenetics/ ucm083378.htm), a comprehensive overview of the inventory of genetic variation on a population level is still lacking. Here, we present an extensive data set of human polymorphisms within important pharmacogenes based on two population sequencing projects: the ESP of the National Heart, Lung, and Blood Institute 22 and the 1000 Genomes Project. 23 We provide an overview and classification of variants across populations and assess the contribution of rare variants to overall functional variability. Furthermore, the data presented here deliver new insights into genetic variants that potentially affect drug efficacy and can thus incentivize the adoption of this knowledge into clinical practice.
MATeRIAL AND MeTHODs

Data collection and filtration
A list of important pharmacogenes was collected from http:// www.pharmaadme.org and expanded with genes from the literature that could play a role in the PK or PD. Data on each of the 146 genes were collected from ESP database (http://www.nhlbi. nih.gov/) release ESP6500SI-V2 22 
where SUM(MAF) is the aggregated minor allele frequencies and n is the allele sample size for European Americans or African Americans, respectively. All chromosome files were obtained from http://ftp.1000genomes.ebi.ac.uk/vol1/ ftp/phase1/analysis_results/supporting/accessible_genome_ masks/ and analyzed using UGENE (http://ugene.unipro.ru). Gene coordinates were obtained from GeneCards (version 3.12.396 26 May 2015).
Quality assessment of sequencing methods
The suitability of short-read sequencing technologies was assessed as described by Drögemöller et al. 24 GC contents and gene paralogues were identified using Ensembl BioMart (http://www.ensembl.org/biomart/martview/ 3f677381f1ad-c3869a4976e7dfc4de22). The inaccessible genomic fraction that is not reliably readable by short-read sequencing technologies was calculated using data provided by the 1000 Genomes Project ("strict mask") in Python.
Computational predictions of functional effects of nonsynonymous variants
Functionality of variants was assessed as in the work by Fujikura et al. 6 and references therein. Additionally, SNPs 3D 25 was used to incorporate structural considerations into the functionality assessments. SNPs 3D scores less than 0 were considered deleterious following cutoff values from the respective publication.
statistical analyses
Statistical analyses were performed using Excel (Microsoft) and Prism 6 (GraphPad software). For comparisons between two groups, heteroscedastic two-tailed Student's t-tests were used. P values less than 0.05 were considered statistically significant. Significant differences between standard deviations were calculated using F-tests.
ResULTs
The majority of variants in pharmacogenes are very rare
We chose pharmacogenes on the basis of a consensus list defined by academia and industry representatives and expanded it with further genes of interest implicated in drug PK or PD. As a result, 146 genes were analyzed by integrating data from the 1000 Genomes Project and the ESP of the National Heart, Lung, and Blood Institute (Figure 1a) . By analyzing data from more than 6,500 individuals from two ethnic groups, we detected a total of 19,328 SNVs, 12,152 (62.9%) of which were located in exons (see Supplementary Table S1 online for a complete list of all found exonic variants). Variants were distributed over all genes analyzed with the exception of SULT1A3. SULT1A3 is 99.8% identical to SULT1A4 and shares part of its coding sequence with the SLX1B gene, a highly conserved endonuclease involved in the replication of ribosomal DNA clusters, 26 which could at least partially explain the lack of detected variants.
We found 6,225 and 6,258 variants in ABC (22 genes) and SLC transporter genes (49), respectively. Furthermore, we identified 1,783 variants in phase I enzymes (14) and 2,528 SNVs in phase II enzymes, of which 1,219, 793, 263, and 253 variants were allotted to UGTs (16) , GTSs (14) , SULTs (4), and others (5), respectively (see Supplementary Table S2 online). Among the nuclear receptors in our pharmacogenetic panel (15 genes) we found 1,343 variants, and another 1,191 were detected in pharmacogenes with miscellaneous functions (7 genes, Figure 1b) . Because intronic variants are only byproducts in the ESP that are not systematically covered, we focused our further analyses exclusively on exonic variants.
From these, most variants per gene were detected in ABC transporters (167.3), whereas GSTs showed least variants (32.8).
To directly compare the variability between gene families, we normalized the number of SNVs to the length of the corresponding gene and identified 28.2 ± 12.1 SD SNVs per kilobase pair (kbp) of transcript overall. UGT enzymes (95% CI: 32-38.7 SNVs/kbp), and ABC transporters (95% CI: 26.4-36.2 SNVs/kbp) showed the highest variability, whereas nuclear receptors were most conserved (95% CI: 7.6-14.4 SNVs/kbp; Figure 1c ). It should be noted, however, that the genomic architecture of UGTs might contribute to the consistently high variability because the UGT1A subfamily consists of nine isoforms derived from a single locus that only differs in the first exon. 27 To put these values into perspective, we calculated the genetic variability of 13 CYP genes (CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP2J2, CYP3A4, CYP3A5, CYP4F2), hereafter termed CYP-13, that account for the majority of all phase I drug reactions in humans. The variability of CYP-13 (95% CI: 27.1-45.5 SNVs/ kbp) was similar to that of genes in the UGT family, indicating that some pharmacogenetic gene groups are as variable as the highly diverse CYP gene family.
We detected 312 novel exonic variants with numbers of SNVs ranging from 0 to 10 per individual gene. Overall, most novel SNVs were found in SLC (122 novel variants) and ABC transporters (62; Figure 1d ). Considering individual genes, ABCC12 (10 novel variants), SLCO1B3 (10), and ABCC2 (8) showed the highest numbers of novel SNVs, whereas 29 genes, including VKORC1, CYBR1, PPARA, and HNF4A, harbored none (see Supplementary Table S2 online). The majority of these novel variants (70.5%) were frameshift variants; the rest were classified as coding (16.7%), UTR (9.9%), or splice-site mutations (3.2%).
Importantly, most SNVs we found were either rare (MAF <1%; 92.9%) or very rare (MAF <0.1%; 82.7%), reflecting recent explosive population growth 28 ( Figure 1e ). Most very rare variants were found in UGTs and ABC transporters, thus suggesting increased evolutionary plasticity in these gene classes (Figure 1f) .
Previous studies showed that the quality of short-read sequencing projects can significantly vary between loci and are influenced by, for example, repetitive sequences, high similarity to paralogous genes, and high GC contents, which in turn can impact the fidelity of variant calls. 24 To systematically analyze the complexity of all pharmacogenes, we calculated the fraction of sequence that is classified as inaccessible by short-read sequencing technologies. Notably, the fraction of inaccessible genome was highest in SULT genes, with an average of 73% of genomic intervals deemed inaccessible due to substantial sequence identity. Although we detected a statistically significant correlation between the number of SNVs and the percentage of inaccessible genomes, this correlation was weak and could only explain 3.3% of the differences in variants between genes (R 2 = 0.033, P = 0.03). Importantly, no correlation was detected between the number of novel variants and the inaccessible genome fraction (R 2 = 0.003, P = 0.53), suggesting that novel variants are not calling artifacts.
The majority of sNVs were nonsynonymous
The largest fraction of SNVs in pharmacogenes caused amino acid changes (n = 6,827, 56.2%), whereas 4,047 (33.3%) were synonymous (Figure 2a) . Interestingly, although the extent of missense variants was relatively similar across all pharmacogenes we studied here (55.4 ± 9% SD), this fraction was similar in magnitude but significantly more variable in the CYP supergene family (45.9 ± 33% SD; data derived from ref. 6 ; difference between standard deviations: P < 0.0001).
When only missense variants were considered, ABCA4 (230) and ABCC3 (146) showed the highest numbers of overall variants (Figure 2b) . ABCA4 is a rod cell-specific photoreceptor Original research article transporter, and its variants have been linked to Stargardt disease, a common form of autosomal-recessive macular dystrophy. 29 ABCC3 is highly expressed in liver, and SNVs affect ADR susceptibility to cisplatin. 30 When taking gene length into account, GSTA2 (59.2 SNVs/ kbp), SLCO4A1 (56.2), SLC22A14 (53.6), and SLC22A1 (53) were most variable, whereas RXRA (6) and SULT1A3 (0) were most conserved (see Supplementary Figure S1 online). ABCA1  ABCC10  ABCC6  ABCC1  ABCC3  ABCC12  ABCC2  ABCB5  ABCC8  ABCC4  ABCB11  ABCB1  ABCC9  ABCC5  ABCB4  ABCB6  ABCB8  TAP1  ABCG1  ABCG2  ABCB7  SLCO4A1  SLC28A1  SLCO1B33  SLCO1A2  SLC22A14  SLCO2B1  SLC15A1  SLC22A1  SLC22A10  SLCO5A1  SLCO2A1  SLC19A1  SLC22A16  SLC22A2  SLCO1B1  SLC22A13  SLC28A2  SLC28A3  SLCO6A1  SLC10A2  SLC22A18  SLC22A9  SLC13A2  SLC2A5  SLC22A11  SLC27A1  SLC22A5  SLC5A6  SLC15A2  SLC7A8  SLCO3A16  SLC22A8  SLC13A1  SLCO4C1  SLC10A1  SLC22A7  SLC2A4  SLCO1C1  SLC22A4  SLC29A2  SLC22A6  SLC22A17  SLC7A5  SLC22A15  SLC6A6  SLC22A3  SLC13A3  SLC29A1  SLC16A1   0   50   100   150   200   POR  DPYD  ALDH4A1  CES1  CES2  EPHX1  CYB5R3  FMO3  ALDH5A1  CYB5R2  ALDH6A1  CYB5R4  CYB5R1  VKORC1  UGT2A1  UGT1A4  UGT1A3  UGT1A10  UGT2B11  UGT2B4  UGT1A9  UGT1A5  UGT1A8  UGT2B7  UGT1A7  UGT2B15  UGT2B28  SULT1A1  UGT1A6  UGT1A1  UGT2B17  SULT1A2  GSTA2  NAT2  GSTA1  SULT1B1  GSTP1  GSTA3  GSTO2  NAT1  GSTM4  GSTO1  TPMT  GSTM2  GSTA5  GSTM3  OTC  NAGS  GSTA4  GSTM1  GSTT1  GSTT2  SULT1A3  AHR  NR1I2  HNF4A  ESR1  NR3C1  NR1H2  PPARA  VDR  NR1I3  NR1H3  PPARG  NR0B2  PPARD  NR1H4  RXRA  POLG  CPS1  ASL  PROS1  ASS1  G6PD Original research article Variants in GSTA2 are predictive of the outcome of allogenic stem cell transplantations at preparative stages.
17 SLC22A1 encodes hOCT1, a broad spectrum transporter that impacts PK of the antidiabetic compound metformin, as well as multiple other antiviral and anticancer drugs such as lamivudine and imatinib. 31 Previous studies estimated that nonsense variants that affect stop-codons, caused frameshifts or occurred in splice sites account for one-third of inherited genetic disorders and are of fundamental importance for human disease. 32 Hence, we analyzed the contribution of nonsense variants and found that, overall, 4.8% of variants were such variations, an abundance, which exceeds the value obtained for all GENCODE regions (1.3%). 23 Relative to the total number of variants detected in each gene family, GSTs and UGTs showed the highest incidences of nonsense variants, with GSTO2, GSTM2, and UGT1A7 having the highest fractions (Figure 2c) .
In silico prediction of functional effects of 12,152 sNVs
Next, we assessed the functional impacts of variants using in silico prediction algorithms. To this end, we used an array of static and machine learning algorithms and evaluated their predictive power on a panel of 24 pharmacogene variants whose functional effects had previously been experimentally and/or clinically validated (see Supplementary Table S3 and Supplementary References online). PolyPhen-2, SIFT, and SNPs 3D classified 17/24 (71%), 17/24 (71%), and 13/24 (54%) missense variants as putatively deleterious, respectively. When integrating all algorithms, 21/24 (88%) validated functional variants were flagged as potentially damaging. Three functional missense variants in ABCB11 (rs11568357), ABCG2 (rs2231142), and GSTP1 (rs1695) were classified as benign by all algorithms, indicating that their predictive power is still not optimal.
We complemented our functionality assessments with genomic evolutionary rate profiling and Grantham scores. Furthermore, we considered all variants that affected stop codons or resulted in frameshifts or splice defects to be putatively functional. As a result, we classified 6,750 SNVs as putatively functional, with the highest numbers of deleterious mutations being in ABCA4 (236) and ABCC10 (145). Functional variants primarily caused amino acid changes (79.8%), followed by synonymous (9.9%) and frameshift (3.6%) variants (Figure 3a) .
We then analyzed the extent of functional polymorphisms across all 146 pharmacogenes (Figure 3b ) and the CYP-13 (see Supplementary Figure S2 online). Thus, we calculated the average numbers of functional variants within each gene and determined which fraction of this functional variation was attributed to rare (MAF <1%) and common (MAF ≥1%) variants. Interestingly, the extent of rare functional variants differed considerably between pharmacogenes from 0.7% for SLC15A2 to 100% for, for example, NR1I3 and was not significantly different compared with CYP genes (P = 0.33 compared with other phase I enzymes, P = 0.65 compared with all 146 pharmacogenes).
Genetic variants differ between individuals of european or African descent
To predict the clinical impact of genetic variants, it is important to consider their distributions and frequencies across different populations. We thus analyzed the variant distributions in populations with European and African ancestry. Interestingly, the majority of variants in pharmacogenes (72%) were populationspecific (5,100 and 3,977 for Europeans and Africans, respectively, Figure 4a ) and, unlike in the CYP supergene family, the proportion of very rare pharmacogene variants was higher in Europeans than in Africans 6 (Figure 4b ). Each individual of European descent harbored, on average, a total of 100.8 SNVs, whereas the number of variants observed in Africans was 121.4. Highest variation rates in European Americans were observed in UGT2B28 (3.21), ABCC6 (2.92), and ABCB5 (2.31), whereas in Africans ABCA1 (3.8), ABCA4 (3.33), and ABCC12 (3.21) were most variable (Figure 4c) . Variants in the ABCC6 gene have been linked to docetaxel and thalidomide response, 33 whereas SNVs in ABCA1 have been shown to significantly associate with response to several statins, 34 thus indicating potential population-specific effects of statin intake. Some genes showed tremendous differences in their variation rate between European and African Americans; Combined, our findings indicate that the genetic variability in clinically relevant pharmacogenes differs considerably between European and African Americans, and they pinpoint potential priority genes for population-adjusted genetic profiling strategies.
DIsCUssION
In the study presented here, we detected a total of 12,152 exonic SNVs in 146 pharmacogenes with clinically important roles, of which the majority were rare (MAF <1%, 92.9%) or very rare (MAF <0.1%, 82.7%). This emphasizes the need to expand the scope from candidate gene analyses in phenotypically different individuals and classical genome-wide association studies that only consider common genetic variants to unbiased sequencing-based approaches. Yet, current sequencing-based technologies like whole-genome sequencing and whole-exome sequencing can face limitations in highly repetitive genomic loci and highly paralogous gene families. To this end, we systematically assessed the fraction of sequence that poses problems for reliable variant calls and only found a weak correlation to the number of SNVs found (R 2 = 0.033, P = 0.03). Thus, short-read sequencing seems suitable for analyzing genetic variation in the pharmacogenes selected here. Nevertheless, it is recommended to validate candidate variants of interest by, for example, classical Sanger sequencing.
Using an array of static and machine learning approaches that consider amino acid physiochemical properties, solvent accessibility as well as structural data, 6,750 SNVs (55.5%) were flagged as putatively functional. Interestingly, when analyzing the contribution of rare variants to putative gene functionality, we found that the extent to which rare variants contribute to functional effects differed significantly between genes. On the basis of these data, we approximated to what extent rare variants contribute to overall interindividual variability in drug response. A previous study showed that rare variants in SLCO1B1 explained 17.8% of the variability in clinical efficacy and toxicity of methotrexate treatment and had larger effect sizes than common variants, thus highlighting the importance of rare variants for pharmacogenetic phenotypes. 35 Consistent with these findings, we observed that 12.7% of functional variation in SLCO1B1 was attributed to rare variants in our data set. We then extrapolated these values to the overall contributions of rare variants in the pharmacogene panel analyzed. Importantly, 31.9% of the inherited interindividual variation in these genes was found to be attributed to rare variants, which is approximately 2.5-fold higher than the value observed in SLCO1B1. We thus concluded that the contribution of rare variants to phenotypic consequences is clinically relevant, and we estimated that approximately 30-40% of the overall functional variability in pharmacogenes is caused by rare variants with MAF <1%. This value is similar to the 28.7% of functionality that is putatively explained by rare variants in the CYP-13. Yet, it has to be noted that these estimations are based on the contribution of rare variants to clinical treatment outcome of a single drug and gene and require further experimental validations. Figure 3 The fraction of functional variability that is attributed to rare and common variants differs strongly between genes. (a) Most putatively functional variants caused amino acid changes (79.8%) or occurred in conserved synonymous bases (9.9%). (b) The probability that a functional variant in a pharmacogene is common (MAF ≥1%, shown in blue) or rare (MAF <1%, red) was calculated for all 146 genes in our panel. Importantly, the fraction of functional variation that is allotted to rare variants differs considerably between genes. Genes within each class are ordered by the total number of functional variants found. ABCA4  ABCC10  ABCA1  ABCC12  ABCC2  ABCC3  ABCC6  ABCB5  ABCC1  ABCC8  ABCC4  ABCB4  ABCB1  ABCB11  ABCC5  ABCB6  ABCC9  ABCB8  TAP1  ABCG2  ABCG1  ABCB7  SLCO1A2  SLCO1B3  SLCO4A1  SLC28A1  SLC15A1  SLC28A2  SLCO2A1  SLC22A2  SLCO5A1  SLC22A10  SLC22A13  SLC22A14  SLC27A1  SLC22A1  SLCO2B1  SLC7A8  SLC22A5  SLC10A2  SLC10A1  SLC22A16  SLCO1B1  SLCO6A1  SLC13A1  SLC13A2  SLC28A3  SLC22A9  SLCO1C1  SLC2A4  SLCO4C1  SLC19A1  SLC2A5  SLCO3A1  SLC22A11  SLC29A2  SLC15A2  SLC22A8  SLC22A4  SLC22A18  SLC22A7  SLC22A3  SLC22A17  SLC5A6  SLC13A3  SLC22A15  SLC22A6  SLC6A6  SLC29A1  SLC7A5  SLC16A1   0%   50%   100%   DPYD  POR  ALDH4A1  ALDH6A1  CES2  FMO3  CES1  ALDH5A1  CYB5R2  EPHX1  CYB5R3  CYB5R1  CYB5R4  VKORC1  UGT2A1  UGT1A4  UGT1A10  UGT1A3  UGT1A7  UGT1A9  UGT1A8  UGT2B11  UGT2B4  UGT1A5  UGT1A1  UGT1A6  UGT2B15  UGT2B7  SULT1A1  UGT2B17  SULT1A2  GSTP1  GSTO2  SULT1B1  UGT2B28  GSTA1  GSTA2  GSTA3  NAT2  OTC  NAGS  GSTM2  GSTM3  GSTO1  TPMT  GSTM4  NAT1  GSTT1  GSTA4  GSTA5  GSTM1  GSTT2  NR1I2  AHR  HNF4A  NR1H3  VDR  PPARA  NR1I3  ESR1  NR3C1  NR0B2  NR1H2  PPARG  PPARD  NR1H4  RXRA  CPS1  POLG  ASS1  PROS1  ASL  G6PD ABCA4  ABCC8  ABCC4  ABCC12  ABCC1  ABCC5  ABCB1  ABCC2  ABCB11  ABCB4  TAP1  ABCC3  ABCC10  ABCB8  ABCB6  ABCB7  ABCG1  ABCG2  ABCC9  SLCO2A1  SLC22A5  SLC22A1  SLC28A3  SLCO1B33  SLCO1A2  SLC19A1  SLC16A1  SLC29A2  SLC6A6  SLC13A3  SLC28A2  SLCO1B1  SLC2A5  SLC28A1  SLC22A4  SLC15A1  SLC29A1  SLC22A3  SLC10A1  SLC15A2  SLC22A14  SLC13A1  SLCO2B1  SLC13A2  SLC10A2  SLC5A6  SLC22A11  SLCO4A1  SLC22A15  SLC22A8  SLC22A9  SLCO3A16  SLCO1C1  SLC27A1  SLC22A17  SLCO4C1  SLCO5A1  SLC22A6  SLC22A10  SLC22A13  SLC7A5  SLC22A16  SLCO6A1  SLC22A7  SLC2A4  SLC7A8  SLC22A18  SLC22A2   0   1   2   3   ALDH4A1  CYB5R2  POR  FMO3  EPHX1  DPYD  CYB5R3  CES1  ALDH5A1  ALDH6A1  CYB5R1  CYB5R4  VKORC1  CES2  UGT2B28  NAT2  UGT1A3  UGT1A6  SULT1A1  UGT2B7  UGT1A5  UGT2B11  UGT1A7  UGT2B15  GSTP1  UGT2B17  GSTA2  UGT2A1  GSTM1  GSTM3  NAGS  SULT1A2  UGT1A4  UGT1A8  UGT2B4  GSTO2  SULT1B1  GSTO1  GSTA1  OTC  GSTM2  TPMT  GSTT2  UGT1A10  GSTM4  NAT1  GSTT1  GSTA5  GSTA3  GSTA4  UGT1A9  UGT1A1  SULT1A3  ESR1  VDR  NR1I2  NR1H3  NR1H2  AHR  PPARD  NR3C1  NR1I3  PPARG  HNF4A  NR0B2  NR1H4  PPARA  RXRA  CPS1  POLG  PROC  G6PD  PROS1  ASS1 Furthermore, we analyzed the genetic variability in pharmacogenes in American individuals of European and African descent and found that the genetic diversity differed substantially between individuals of African and European descent, consistent with previous studies. 6, 28 Genetic variability was overall higher in Africans because of complex population dynamics, substantial variability in environmental factors, and differential exposure to infectious disease. 36 Yet, the genetic composition of indigenous European, and especially African, populations can differ tremendously from the genetic inventory observed in European and African Americans, and thus extrapolation of these findings needs to be performed cautiously.
Although most genes showed increased variability in Africans, there were notable exceptions such as ABCB1, which encodes the multidrug resistance transporter P-Gp, and SLC22A3, encoding a transporter for the antidiabetic drug metformin, 37 that were more variable in Europeans. The genetic differences on a population level in pharmacogenes provided here can serve as a reference for the design of randomized controlled trials, because the participants of such trials are generally not representative of the target population and might lack external validity. 38 It is therefore reasonable to assume that extrapolation of trial results becomes more problematic with increasing genetic variability in loci of importance for trial compound PK and PD, and thus optimal treatment regimens and susceptibility to ADRs can differ between populations.
To improve pharmacogenetic utility and human health, the future key task will be to identify variants that are clinically relevant and that provide cost-effective targets for pharmacogenetic testing. While sequencing costs continue to decline, the costs of analysis, annotation, and data management decrease (if at all) to a much lesser extent, thus shifting the bottleneck away from technical considerations toward downstream analyses. 39 Importantly, current prediction algorithms are trained on data sets linked to disease. Yet, accurate functionality predictions of variants that do not cause phenotypes per se but only modulate PK and PD and result in phenotypes only in certain contexts might follow different rules. Thus, such predictions would benefit from approaches that parameterize the prediction model using sets of validated variants with pharmacogenetic impacts. Hence, there is a need for larger panels of experimentally validated genetic pharmacogene variants that, in turn, will facilitate more accurate in silico predictions of uncharacterized variants. Furthermore, current functionality prediction algorithms generally do not consider haplotype phases because these are usually poorly resolved by short-read sequencing. For instance, the variant rs12248560 is responsible for the increased activity of the CYP2C19*17 allele. Yet, when combined with rs28399504, the resulting haplotype (CYP2C19*4B) results in a loss-of-function allele, demonstrating that the effect of SNVs can be very different, depending on whether they occur isolated or in combination with other variants. As a consequence, accurately phased data can serve as a better pharmacogenetic marker than individual SNVs and can improve predictability of drug response. 40 Although the extent of genetic variations in transporters, phase I and II enzymes, and nuclear receptors is considerable, current pharmacogenetic tests only probe a minute selection of variants and thus do not capture the true interindividual variability, resulting in potentially flawed phenotype predictions and avoidable lack of treatment efficacy. Based on our variant quantifications, we estimate that approximately 30-40% of functional variability can be allotted to rare variants that are not commonly considered in genetic tests. The clinical implementation of strategies that accommodate for this rare genetic variability is, however, not easy because precision medicine initiatives in which drug treatment is adjusted to comply with the genetic makeup of the specific patient will be complicated by the large extent of rare variants. In principle, two levels of genetic analyses must be considered: (i) most pharmacogenomic drug labels relate to variations in one or a few specific genes and the data presented here indicate that complete gene sequencing coupled to reliable functionality assessment of the variants found would be required and (ii) the functional impact of the extensive genetic variation in all pharmacogenes with relevance for a specific drug treatment must be considered. In contrast to the current pharmacogenomic labels for which the findings of many clinical studies are often available to inform decisions regarding drug choice and dose, it would require major effort to directly link interindividual differences in drug response to the presence of rare pharmacogenetic variations.
In conclusion, the results provided here shed light on the genetic diversity of pharmacogenes and aim to incentivize the use of comprehensive sequencing-based approaches for pharmacokinetic and pharmacodynamic phenotyping. Furthermore, the described variants of interest can serve as a basis for experimental validations and the development of future genotyping platforms.
